CANTARGIA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.728 SEK | -1.95% |
|
-8.04% | -0.27% |
| Sales 2023 | - | Sales 2024 * | - | Capitalization | 685M 62.73M |
|---|---|---|---|---|---|
| Net income 2023 | -280M -25.65M | Net income 2024 * | -280M -25.65M | EV / Sales 2023 | - |
| Net cash position 2023 | 195M 17.84M | Net Debt 2024 * | 56.6M 5.18M | EV / Sales 2024 * | - |
| P/E ratio 2023 |
-2.27
x | P/E ratio 2024 * |
-1.73
x | Employees | 22 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 91.78% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cantargia AB
More press releases
| 1 day | -1.95% | ||
| 1 week | -8.04% | ||
| Current month | +6.82% | ||
| 1 month | +25.02% | ||
| 3 months | +10.89% | ||
| 6 months | -11.95% | ||
| Current year | -0.27% |
1 week
3.57
4.05
1 month
2.814.80
Current year
2.564.80
1 year
2.566.70
3 years
2.5635.78
5 years
2.5671.80
10 years
2.5671.80
| Managers | Title | Age | Since |
|---|---|---|---|
Göran Forsberg
CEO | Chief Executive Officer | 61 | 14-07-08 |
Patrik Renblad
DFI | Director of Finance/CFO | 54 | 23-06-14 |
David Liberg
CTO | Chief Tech/Sci/R&D Officer | 55 | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Magnus Nilsson
BRD | Director/Board Member | 68 | 21-05-25 |
| Chairman | 64 | 15-12-31 | |
Damian Marron
BRD | Director/Board Member | 62 | 21-05-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 3.728 | -1.95% | 267,532 |
| 24-04-18 | 3.802 | -4.47% | 344,626 |
| 24-04-17 | 3.98 | +4.19% | 263,248 |
| 24-04-16 | 3.82 | +4.66% | 364,926 |
| 24-04-15 | 3.65 | -9.97% | 948,927 |
Delayed Quote Nasdaq Stockholm, April 19, 2024 at 11:29 am EDT
More quotes
Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
Calendar
2024-05-21
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.728
SEK
Average target price
12.67
SEK
Spread / Average Target
+239.77%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.27% | 63.93M | |
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B |
- Stock Market
- Equities
- CANTA Stock
